Changes in Hong Kong stocks | Verishibo-B (09887) rose more than 6%, and Velisin's first-line treatment of hepatocellular carcinoma phase II research has entered the expansion stage

The Zhitong Finance App learned that Weilizhibo-B (09887) rose by more than 6%, with a cumulative increase of more than 36% during the month. As of press release, it rose 6.07% to HK$73.35, with a turnover of HK$131 million.

According to the news, Weilizhibo recently announced that the first-line clinical study of PD-L1/4-1BB bispecific antibody Verisin (LBL-024) for the first-line treatment of hepatocellular carcinoma, which was independently developed by the company, completed the safety introduction period evaluation after expert review and successfully entered the expansion phase.

According to public information, Velisin has shown strong efficacy signals and breakthrough treatment potential in various tumors such as extrapulmonary neuroendocrine cancer, non-small cell lung cancer, small cell lung cancer, and biliary tract cancer. Relying on the conditional activation design of the X-body® platform, its good safety was verified in nearly 800 patients. This time, it has been proven again in liver cancer, further consolidating Velisin's safety base as an IO 2.0 pan-tumor cornerstone therapy.